FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **CV01382K**	SERIAL NO.: **10/057,629**
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: **Harry R. Davis**	
(Use several sheets if necessary)	FILING DATE: **January 25, 2002**	GROUP: **1614**

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AA	***Exhibit A:*** SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary
	AB	***Exhibit B:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AC	***Exhibit C:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AD	***Exhibit D:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AE	***Exhibit E:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AF	***Exhibit F:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AG	***Exhibit G:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AH	***Exhibit H:*** SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AI	***Exhibit 1:*** Master Sheet for the SCH 58235 and Lovastatin Research Study, *Schering-Plough Research Institute* (Protocol No. C906-411), page 1576-1585
	AJ	***Exhibit 2:*** Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, *Peninsular Testing Corporation*, page 106-112
	AK	***Exhibit 3:*** Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," *Schering-Plough Research Institute* (Protocol No. C98-010), page 1558-1566
	AL	***Exhibit 4:*** Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, *Peninsular Testing Corporation*, page 124-130
	AM	***Exhibit 5:*** Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," *Schering-Plough Research Institute*, page 1-8

EXAMINER	DATE CONSIDERED
	10/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.